Revenue ($USD) : $537,840,000 R&D spend : $206,085,000.00 Employees : 1,320 Fiscal year end : 12/31/22 CEO : Asaf Danziger
Novocure specializes in developing therapies for difficult-to-treat tumors. The oncology company's tumor treating fields technology (“TTFields”) is FDA-approved for recurrent and newly diagnosed glioblastoma and mesothelioma. In June 2023, the company said a phase 3 clinical trial found TTFields with standard therapies improved survival for non-small cell lung cancer patients. The company is also studying ovarian, brain and pancreatic cancer. Novocure has its U.S. headquarters in Portsmouth, New Hampshire and R&D operations in Haifa, Israel. –JH